Drug makers that agree to provide access to experimental treatments under the Right to Try act may be putting the future approval of their treatments at risk, some CEOs argue.
Category: Forbes
Should Planes Have Locking Overhead Bins To Protect Passengers From Themselves?
Passengers do not respond rationally to aircraft accidents, putting their luggage before their lives. Would locked overhead bins solve this problem?
Blockchain For Scientists Takes On Elsevier, The Business The Internet Couldn’t Kill
Could blockchain be what brings science’s untouchable publishing giants down? Anita Schjøll Brede, cofounder and CEO at Iris.AI—one of Europe’s hottest artificial intelligence companies—hopes so. She explains how Project Aiur works at CogX AI festival, part of London Tech Week.
How Many Extra Calories Are You Getting From Food At Work?
A study presented at the Nutrition 2018 meeting measured how many people are getting free food at work and what comes with that.
AMA Intensifies Push For Gun Control Ahead Of Midterm Elections
The American Medical Association Tuesday endorsed bans on bump stocks, assault weapons and support raising the legal age of purchasing ammunition and firearms from 18 to 21.
AI And Biotech Companies In The East And West Invest In Combating Aging
The fields of Artificial Intelligence (AI) and regenerative medicine are putting their money on combating aging and age-related diseases, and the benefits are likely to be immense.
Art Of The Deal: Trump Looks To Trade Cannabis Legalization for Justice Department Nominees
Colorado’s Republican Senator may have figured out a way to pierce the federal cannabis prohibition dam
NIH Targets $500 Million At Opioid Crisis
The National Institutes of Health is explaining how it will spend $500 million in research funds Congress appropriated to address the current opioid crisis.
Nurse Practitioner Demand Surges As Insurers Push Retail Care
Only family physicians and psychiatrists are more in demand than nurse practitioners, the 2018 healthcare staffing report from Merritt Hawkins said.
Pharma R&D Investments Moderating, But Still High
However, it is clear that the pharmaceutical industry is going to continue to invest in R&D at a pretty healthy rate for the foreseeable future.
